Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

Pages

12953 items
12:28 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Other Financial News

1315 closes $300M 1315 Capital II fund

1315 Capital LLC (Philadelphia, Pa.) closed its 1315 Capital II fund on Feb. 12 at over $300 million, exceeding its $250 million target. The fund will invest $10-$30 million per company. The company, which has...
12:27 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Avid raises $23M in follow-on

Contract development and manufacturing company Avid Bioservices Inc. (NASDAQ:CDMO) raised $23.2 million through the sale of 10.3 million shares at $2.25 in a follow-on underwritten by Wells Fargo, H.C. Wainwright and Roth. The figures include...
12:26 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Arcus proposes $100M IPO

Cancer immunotherapy company Arcus Biosciences Inc. (Hayward, Calif.) proposed on Feb. 16 to raise $100 million in an IPO on NYSE underwritten by Citigroup, Goldman Sachs and Leerink. Arcus Biosciences Inc., Hayward, Calif.  ...
12:25 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Ascendis raises $225M in bumped-up follow-on

Endocrinology company Ascendis Pharma A/S (NASDAQ:ASND) raised $225 million on Feb. 22 through the sale of 3.9 million ADSs at $57 in a bumped-up follow-on underwritten by J.P. Morgan, BofA Merrill Lynch, Credit Suisse, Wells...
12:25 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Aimmune raises $176M in bumped up follow-on

Allergy play Aimmune Therapeutics Inc. (NASDAQ:AIMT) raised $176 million on Feb. 22 through the sale of 5.5 million shares at $32 in a bumped-up follow-on. Underwriters were BofA Merrill Lynch, Cantor Fitzgerald, Piper Jaffray, Credit...
12:25 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Ra raises $50.4M in follow-on

Complement-mediated disease company Ra Pharmaceuticals Inc. (NASDAQ:RARX) raised $50.4 million on Feb. 14 through the sale of 8.4 million shares at $6 in a follow-on underwritten by Credit Suisse, Jefferies, BMO Capital Markets and SunTrust...
12:24 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Pieris raises $50.6M in follow-on

Anticalin company Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) raised $50.6 million through the sale of 6.3 million shares at $8 in a follow-on underwritten by Jefferies, Cowen and Evercore ISI. The figures include the sale of an...
12:24 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Pacific raises $30M in follow-on

Sequencing company Pacific Biosciences of California Inc. (NASDAQ:PACB) raised $30 million on Feb. 13 through the sale of 12.5 million shares at $2.40 in a follow-on underwritten by Cantor. The price is a 6% discount to...
12:24 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

miRagen raises $38.5M in follow-on

MicroRNA company miRagen Therapeutics Inc. (NASDAQ:MGEN) raised $38.5 million on Feb. 8 through the sale of 7 million shares at $5.50 in a follow-on underwritten by Jefferies, Evercore, Deutsche Bank, Wedbush and Oppenheimer. The price is...
12:22 PM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

BioXcel Therapeutics proposes $69M IPO

Artificial intelligence company BioXcel Therapeutics Inc. (Branford, Conn.) proposed on Feb. 13 to raise up to $69 million in an IPO on NASDAQ underwritten by Barclays, UBS Securities, BMO Capital Markets and Canaccord Genuity. BioXcel...

Pages